… with better bioavailability and higher potency in pancreatic cancer in vitro and xenograft models.
… of curcumin analogs and their potential role as novel therapeutics for pancreatic cancer. …

… novel curcumin analogues were synthesized and screened for anticancer activity. New
analogues that exhibit growth-… of new curcumin analogues and their abilities to induce cell growth …

… inhibit mouse mammary tumor growth in vivo. Both curcumin and its analogs have been shown
… , and found the compounds to be more active than curcumin. As a follow-up, a number of …

… There are several curcumin analogues that have already been reported, such as … efficacy
of new curcumin analogues, GO-Y030, FLLL-11, and FLLL-12 in colorectal cancer cell lines. …

… The oncogenic pathways inhibited by curcumin encompass the members of epidermal
growth factor receptors (EGFR and erbB2), sonic hedgehog (SHH)/GLIs and Wnt/β-catenin and …

… that curcumin analogues EF31 … growth factors simultaneously. In this study, we evaluated
and compared the antiangiogenic effects of curcumin, EF31 and UBS109 in pancreatic cancer …

… the curcumin analogues, FLLL11 and FLLL12, are potent agents in inhibiting STAT3 and
AKT phosphorylation in human pancreatic cancer cells and are more active than curcumin in …

… curcumin analogs towards CRPC cells. For this purpose, PC3 and DU145 cells were treated
with a series of curcumin analogs … Both analogs increased the number of cells in the G2/M …

… analogues, multiple approaches are being sought to obtain more stable, soluble and effective
analogues of … focuses on the progress of these approaches to more potent CU analogues. …

The transcription factor NF‐κB plays a central role in angiogenesis in colorectal cancer (CRC).
Curcumin is a natural dietary product that inhibits NF‐κB. The objective of this study is to …